Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 55%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health has demonstrated robust growth with a 7% year-over-year increase despite challenging comparisons, indicating strong market demand for its liquid-based cancer tests. The company's commanding market position is highlighted by its over 50% share in the circulating genomic profiling liquid biopsy segment and nearly 30% year-over-year growth in this area, along with anticipated increases in average selling prices and test volumes from new reimbursements and pricing strategies. Additionally, Guardant's proactive approach to expand testing frequency and services suggests a promising trajectory for revenue growth, positioning the company favorably within the evolving landscape of cancer diagnostics.

Bears say

The financial analysis of Guardant Health indicates a negative outlook primarily due to concerns surrounding reimbursement dynamics, which are expected to pressure the average selling price (ASP) and pose direct risks to revenue estimates. Additionally, the pending implementation of PAMA regulations could lead to a significant one-time revenue reduction of approximately $100 million, further compounding the company’s financial challenges. Furthermore, uncertainties in the regulatory landscape for multi-cancer early detection (MCED) tests may hinder reimbursement and adoption of Guardant's assays, ultimately affecting the company's profitability and future outlook.

GH has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 55% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 20 analysts, GH has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $116.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $116.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.